CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 55 enrolled
Drug / intervention
TrueTear Intranasal Tear Neurostimulatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03719885
NCT03719885N/ACompleted
CompareCT.gov

Prospective Controlled Study of Intranasal Tear Neurostimulation for Sjogrens Patients With Dry Eye Disease

University of Pennsylvania·interventional·Posted Oct 25, 2018·Updated Jul 7, 2023

In Brief

A clinical study evaluating TrueTear Intranasal Tear Neurostimulator for Dry Eye Syndromes and Sjogren's Syndrome. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate acute tear production produced by the intranasal tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency. Our primary goal is to evaluate whether Sjögrens patients respond to this intervention and whether there is a baseline tear production level below which these patients do not respond.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes, Sjogren's Syndrome
CountriesUnited States
CollaboratorsAllergan

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 25, 2018
Enrollment StartDec 1, 2018
Primary CompletionApr 25, 2019
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.7 years ago

Interventions

TrueTear Intranasal Tear Neurostimulatordevice

This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease